<DOC>
	<DOCNO>NCT00768287</DOCNO>
	<brief_summary>To evaluate safety ( acute effect associate infusion , inhibitor development ) , pharmacokinetics ( PK ) , efficacy respect breakthrough bleed prophylaxis respect control hemorrhage prophylaxis demand group IB1001 subject hemophilia B .</brief_summary>
	<brief_title>Study Recombinant Factor IX Product , IB1001 , Subjects With Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>1 . Patient must willing give write Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve informed consent , make require study visit , follow instruction enrol study 2 . Severe ( factor IX activity ≤2 U/dL ) hemophilia B subject demand therapy minimum 3 bleed episode precede 6 month 6 bleed episode precede 12 month ; subject prophylaxis bleed pattern demonstrate prior start prophylaxis 3 . Immunocompetent ( CD4 count &gt; 400/mm3 ) receive immune modulate chemotherapeutic agent 4 . Previously treat patient minimum 150 exposure day factor IX preparation 5 . Platelet count least 150,000/mm3 6 . Liver function : alanine transaminase [ ALT ] aspartate transaminase [ AST ] ≤2 time upper limit normal range 7 . Total bilirubin ≤1.5 time upper limit normal range 8 . Renal function : serum creatinine ≤1.25 time upper limit normal range 9 . Willingness participate trial 1215 month 10 . European Union ( EU ) , Israel , Canada : Age least 12 year body weight ≥40 kilogram participate PK Study Surgical Substudy [ Surgical Substudy apply UK ] ; age least 12 year prophylaxis demand component Treatment Phase Continuation Study United States ( US ) : Age least 12 year body weight ≥40 kilogram participate PK Study Surgical Substudy ; age least 5 year prophylaxis demand component Treatment Phase Continuation Study 11 . Hemoglobin ≥7 g/dL time blood draw 1 . History factor IX inhibitor ≥0.6 Bethesda unit ( BU ) 2 . Existence another coagulation disorder 3 . Evidence thrombotic disease , fibrinolysis , disseminate intravascular coagulation ( DIC ) 4 . Use investigational drug within 30 day prior study entry 5 . On medication could impact hemostasis , aspirin 6 . History poor compliance , serious medical social condition , circumstance , opinion investigator , would interfere participation compliance study protocol 7 . History adverse reaction either plasmaderived factor IX recombinant factor IX interfere subject 's ability treat bleed episode factor IX product</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>